Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized paired-eyes

  • Norihito Doi
  • Taiji SakamotoEmail author
  • Yasushi Sonoda
  • Miho Yasuda
  • Koji Yonemoto
  • Noboru Arimura
  • Eisuke Uchino
  • Tatsuro Ishibashi
Retinal Disorders



The present study was performed to compare the effects of pars plana vitrectomy (PPV) and single intravitreaous triamcinolone acetonide (IVTA) on diabetic macular edema (DME) in paired eyes.


Prospective comparative study on randomized paired-eyes was carried out at two hospitals. Forty eyes of 20 patients with bilateral DME were included. One randomly-selected eye was treated with PPV (PPV group), and the other eye was treated with IVTA (4 mg, IVTA group). The central macular thickness (CMT) measured by optical coherence tomography (OCT) and best-corrected visual acuity (BCVA) were monitored for 12 months after treatment. Changes from baseline and differences between groups were analyzed using a mixed model.


At 1 and 3 months, CMT decreased significantly in the IVTA group compared to baseline (p < 0.0001 both), but CMT then increased gradually and no significant difference was found at 12 months (p = 0.90). In the PPV group, CMT decreased continuously and reached a significant level at 12 months (p < 0.0001). CMT of the IVTA group was significantly less than that of the PPV group at 1 month (p = 0.009); however, there was no significant difference at 3 months. Conversely, CMT was significantly less in the PPV group than in the IVTA group at 12 months (p = 0.0003). The changes of BCVA paralleled those of CMT, but no significant difference was detected between baseline BCVA and any time point.


Despite the short-term improvement, DME recurred 6 months after IVTA, while it remained resolved after PPV. Although this study did not reveal a significant change of BCVA with either treatment, PPV resolved DME more effectively than IVTA at 1 year.


Diabetic retinopathy Corticosteroid Central macular thickness Pars plana vitrectomy Pharmacologic therapy 



We appreciate the technical support by Drs Hiroki Otsuka, MD, and Toshifumi Yamashita, MD.

Grant support

Supported in part by a Grant from the Research Committee on Chorioretinal Degeneration and Optic Atrophy, Ministry of Health, Labor, and Welfare; by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of the Japanese Government.

Conflict of interest



  1. 1.
    Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–927PubMedCrossRefGoogle Scholar
  2. 2.
    Benhamou N, Massin P, Haouchine B, Audren F, Tadayoni R, Gaudric A (2003) Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 135:246–249PubMedCrossRefGoogle Scholar
  3. 3.
    Jonas JB, Kreissig I, Sofker A, Degenring RF (2003) Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121:57–61PubMedCrossRefGoogle Scholar
  4. 4.
    Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I (2004) Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 138:158–160PubMedCrossRefGoogle Scholar
  5. 5.
    Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME (2007) Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743–750PubMedCrossRefGoogle Scholar
  6. 6.
    Grover D, Li TJ, Chong CC (2008) Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev: CD005656Google Scholar
  7. 7.
    Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R (2008) Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 92:76–80PubMedCrossRefGoogle Scholar
  8. 8.
    Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, Abraham P, Campochiaro PA (2009) Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 116(11):2175.e1–2181.e1Google Scholar
  9. 9.
    Diabetic retinopathy clinical research network (2009) Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 127:245–251CrossRefGoogle Scholar
  10. 10.
    Lewis H, Abrams GW, Blumenkranz MS, Campo RV (1992) Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 99:753–759PubMedGoogle Scholar
  11. 11.
    Harbour JW, Smiddy WE, Flynn HW Jr, Rubsamen PE (1996) Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 121:405–413PubMedGoogle Scholar
  12. 12.
    Tachi N, Ogino N (1996) Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol 122:258–260PubMedGoogle Scholar
  13. 13.
    Micelli Ferrari T, Cardascia N, Durante G, Vetrugno M, Cardia L (1999) Pars plana vitrectomy in diabetic macular edema. Doc Ophthalmol 97:471–474PubMedCrossRefGoogle Scholar
  14. 14.
    Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, Garretson BR, Trese MT (2000) Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 130:178–186PubMedCrossRefGoogle Scholar
  15. 15.
    Otani T, Kishi S (2000) Tomographic assessment of vitreous surgery for diabetic macular edema. Am J Ophthalmol 129:487–494PubMedCrossRefGoogle Scholar
  16. 16.
    La Heiji EC HF, Kessels AG, Derhaag PJ (2001) Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefes Arch Clin Exp Ophthalmol 239:264–270CrossRefGoogle Scholar
  17. 17.
    Yamamoto T, Akabane N, Takeuchi S (2001) Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 132:369–377PubMedCrossRefGoogle Scholar
  18. 18.
    Gardner TW, Antonetti AD, Barber AJ, LaNoue KF, Levison SW (2002) Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 47:S253–S262PubMedCrossRefGoogle Scholar
  19. 19.
    Otani T, Kishi S (2002) A controlled study of vitrectomy for diabetic macular edema. Am J Ophthalmol 134:214–219PubMedCrossRefGoogle Scholar
  20. 20.
    Massin P, Duguid G, Erginay A, Haouchine B, Gaudric A (2003) Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 135:169–177PubMedCrossRefGoogle Scholar
  21. 21.
    Yamamoto T, Hitani K, Tsukahara I, Yamamoto S, Kawasaki R, Yamashita H, Takeuchi S (2003) Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema. Am J Ophthalmol 135:14–19PubMedCrossRefGoogle Scholar
  22. 22.
    Yanyali A, Nohutcu AF, Horozoglu F, Celik E (2005) Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol 139:795–801PubMedCrossRefGoogle Scholar
  23. 23.
    Kumar A, Sinha S, Azad R, Sharma YR, Vohra R (2007) Comparative evaluation of vitrectomy and dye-enhanced ILM peel with grid laser in diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 245:360–368PubMedCrossRefGoogle Scholar
  24. 24.
    Shimonagano Y, Makiuchi R, Miyazaki M, Doi N, Uemura A, Sakamoto T (2007) Results of visual acuity and foveal thickness in diabetic macular edema after vitrectomy. Jpn J Ophthalmol 51:204–209PubMedCrossRefGoogle Scholar
  25. 25.
    Shimonagano Y, Doi N, Noda Y, Uemura A, Sakamoto T (2007) Recurrence of diabetic macular edema after intravitreous injection of triamcinolone following vitrectomy. Jpn J Ophthalmol 51:278–284PubMedCrossRefGoogle Scholar
  26. 26.
    Yamakiri K, Sakamoto T, Noda Y, Nakahara M, Ogino N, Kubota T, Yokoyama M, Furukawa M, Sonoda Y, Yamada T, Doi N, Enaida H, Hata Y, Ishibashi T (2007) Reduced incidence of intraoperative complications in a multicenter controlled clinical trial of triamcinolone in vitrectomy. Ophthalmology 114:289–296PubMedCrossRefGoogle Scholar
  27. 27.
    Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, Nishida K (2008) Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 145:854–861PubMedCrossRefGoogle Scholar
  28. 28.
    Hartley KL, Smiddy WE, Flynn HW Jr, Murray TG (2008) Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina 28:410–419PubMedCrossRefGoogle Scholar
  29. 29.
    Kumagai K, Furukawa M, Ogino N, Larson E, Iwaki M, Tachi N (2009) Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 29:464–472PubMedCrossRefGoogle Scholar
  30. 30.
    Stefansson E (2009) Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 247:147–163PubMedCrossRefGoogle Scholar
  31. 31.
    Diabetic retinopathy clinical research network (2008) A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115:1447–1449CrossRefGoogle Scholar
  32. 32.
    Bressler NM, Edwards AR, Beck RW, Flaxel CJ, Glassman AR, Ip MS, Kollman C, Kuppermann BD, Stone TW (2009) Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol 127:1566–1571PubMedCrossRefGoogle Scholar
  33. 33.
    Thomas D, Bunce C, Moorman C, Laidlaw DA (2005) A randomised controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema. Br J Ophthalmol 89:81–86PubMedCrossRefGoogle Scholar
  34. 34.
    Gillies MC, Simpson JM, Gaston C, Hunt G, Ali H, Zhu M, Sutter F (2009) Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 116:2182–2187PubMedCrossRefGoogle Scholar
  35. 35.
    Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F, Glassman AR, Ip MS, Miller KM (2010) Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 117:946–953PubMedCrossRefGoogle Scholar
  36. 36.
    Tong JP, Lam DS, Chan WM, Choy KW, Chan KP, Pang CP (2006) Effects of triamcinolone on the expression of VEGF and PEDF in human retinal pigment epithelial and human umbilical vein endothelial cells. Mol Vis 12:1490–1495PubMedGoogle Scholar
  37. 37.
    Almawi WY, Beyhum HN, Rahme AA, Rieder MJ (1996) Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 60:563–572PubMedGoogle Scholar
  38. 38.
    Southam DS, Ellis R, Wattie J, Glass W, Inman MD (2008) Goblet cell rebound and airway dysfunction with corticosteroid withdrawal in a mouse model of asthma. Am J Respir Crit Care Med 178:1115–1122PubMedCrossRefGoogle Scholar
  39. 39.
    Gandorfer A (2009) Objective of pharmacologic vitreolysis. Dev Ophthalmol 44:1–6PubMedCrossRefGoogle Scholar
  40. 40.
    Ito M, Okubo A, Sonoda Y, Yamakiri K, Sakamoto T (2006) Intravitreal triamcinolone acetonide for exudative age-related macular degeneration among Japanese patients. Ophthalmologica 220:118–124PubMedCrossRefGoogle Scholar
  41. 41.
    Yamakiri K, Sakamoto T, Noda Y, Nakahara M, Ogino N, Kubota T, Yokoyama M, Furukawa M, Ishibashi T (2008) One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol 246:959–966PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Norihito Doi
    • 1
  • Taiji Sakamoto
    • 1
    Email author
  • Yasushi Sonoda
    • 1
  • Miho Yasuda
    • 2
  • Koji Yonemoto
    • 3
  • Noboru Arimura
    • 1
  • Eisuke Uchino
    • 1
  • Tatsuro Ishibashi
    • 2
  1. 1.Department of Ophthalmology Faculty of MedicineKagoshima University Graduate School of Medicine and Dental SciencesKagoshimaJapan
  2. 2.Kyushu University School of MedicineFukuokaJapan
  3. 3.Biostatics CenterKurume UniversityKurumeJapan

Personalised recommendations